Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Mitacs brings innovation to more people in more places across Canada and around the world.
Learn MoreWe work closely with businesses, researchers, and governments to create new pathways to innovation.
Learn MoreNo matter the size of your budget or scope of your research, Mitacs can help you turn ideas into impact.
Learn MoreThe Mitacs Entrepreneur Awards and the Mitacs Awards celebrate inspiring entrepreneurs and innovators who are galvanizing cutting-edge research across Canada.
Learn MoreDiscover the people, the ideas, the projects, and the partnerships that are making news, and creating meaningful impact across the Canadian innovation ecosystem.
Learn MoreFlavonoids are polyphenolic compounds which give fruits and vegetables their bright colours. Habitual consumption of dietary flavonoids reduces the risk for neurodegenerative disorders such as Parkinson’s disease, stroke and Alzheimer’s disease. Pre-clinical studies performed using animal models for these disorders have convincingly demonstrated that flavonoids not only halt the pathological processes which cause neurodegeneration but also promote recovery after brain damage. These findings and the fact that flavonoids can be consumed safely even in large amounts suggest they be useful treatments for neurodegenerative disorders. With this in mind, we have isolated a flavonoid-enriched fraction from the peel of Nova Scotia apple called AF4. Oral administration of AF4 reduces inflammation, brain damage and motor deficits in mouse models for stroke and multiple sclerosis. The purpose of the present application is to determine whether AF4 also reduces the inflammatory and degenerative events responsible for noise- and cisplatin-induced hearing loss in mice. Hearing loss is a frequent complication of cisplatin therapy for cancer that may occur within the first few days of treatment. Demonstrating that AF4 prevents cisplatin-induced hearing loss in mice would therefore facilitate a clinical trial in cancer patients enabling rapid-proof-of-concept in humans for condition relevant to neurodegenerative disorders.
Dr. George S. Robertson
Matt Nichols, David Aphkhazava & Jin Zhang
Scotia Biosciences
Pharmacy / Pharmacology
Pharmaceuticals
Dalhousie University
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.